[1] IIS Fdn Jimenez Diaz, Ctr Invest Biomed Red Enfermedades Raras CIEMAT C, Unidad Mixta Terapias Avanzadas, Hematopoiet Innovat Therapies Div,Ctr Invest Enfe, Madrid, Spain
[2] Clin Univ Navarra, Hematol & Cell Therapy Dept, IdiSNA, Pamplona, Spain
[3] Cima Univ Navarra, Hematooncol Program, IdiSNA, CIBERONC, Pamplona, Spain
[4] Hosp Univ Navarra, Serv Hematol, IdiSNA, Pamplona, Spain
[5] Univ Hosp Salamanca HUS IBSAL, Hematol Dept, CIBERONC, Salamanca, Spain
[6] Ctr Canc Res IBMCC USALCSIC, Salamanca, Spain
[7] IIS Fdn Jimenez Diaz, Div Hematol & Hemotherapy, Madrid, Spain
[8] Hosp Clin Barcelona, Dept Immunol & Cell Immunotherapy Platform HSJD H, Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[9] Univ Murcia, Virgen Arrixaca Univ Hosp, Stem Cell Transplant & Cell Therapy Unit, Dept Hematol,IMIB Arrixaca, Murcia, Spain
[10] Paul Ehrlich Inst, Div Med Biotechnol, Transposit & Genome Engn, Langen, Germany
[11] Clin Univ Navarra, Immunol & Inmunotherapy Dept, Pamplona, Spain